Sharpen your approach to sleepy patients with a new educational program which plays like an interactive movie. This program emphasizes the primary care physician's role in recognizing and managing obstructive sleep apnea.

Cost: free of charge

BONUS:

Free access to the powerful Arbor Medicus patient history taking program.

You can register and log on to review your patients' progress.

This Patient Toolkit:

- takes a complete general medical history
- takes a detailed sleep history relating to sleepiness
- tracks your patients from visit to visit, according to accepted clinical guidelines for tracking sleep apnea patients.

Target audience includes primary care physicians, nurse practitioners, physician's assistants as well as neurologists and other medical specialists.

Implementation and Method of Physician Participation:
The learner registers in the Arbor Medicus website and begins the course. You may start and stop as time allows, resuming where you left off. No CME credits will be granted.

Thomas Roth, Ph.D.

Sleep Disorders
Clinic & Research Center
Henry Ford Hospital
Detroit, MI

Course Chairman

Michael J. Thorpy, M.D.
Director Sleep-Wake Disorders Center
Montefiore Medical Center

Professor of Neurology
Albert Einstein College of Medicine
Bronx, New York

Click Here to
begin the course

Please note, this program requires:
- Windows Internet Explorer 5.5 or higher
- Windows 98, XP, 2000 or Vista
- Adobe Flash Player 6.0

Course Developer and Narrator:
Edmund Messina, MD
Diplomat of the American Board of Psychiatry
and Neurology (Neurology)

Clinical Associate Professor of Medicine

College of Human Medicine
Michigan State University

This educational module was developed in cooperation with the
FloBase Learning Bank
and meets its educational standards.

2.00 AMA PRA Category 1 Credits™

NOTE: You can start and stop as often as you like. The program continues where you left off. We understand how busy clinical medicine can get, so take it in steps.

Accreditation and Credits
This activity was originally planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) in cooperation with the University of Oklahoma College of Medicine and previously was designated for Prescribed credits by the American Academy of Family Physicians.

Conflict Resolution Statement
The University of Oklahoma College of Medicine, Irwin Brown Office of Continuing Medical Education has reviewed this activity’s planner and speaker disclosure(s) and resolved all identified conflicts of interest, if applicable.

Disclosure Policy
It is the policy of the University of Oklahoma College of Medicine, Irwin Brown Office of Continuing Medical Education to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in these programs are expected to disclose to the program audiences any real or apparent conflict of interest related to the content of their presentation.

Disclosure Information
The University of Oklahoma College of Medicine, Irwin Brown Office of Continuing Medical Education has adopted a policy regarding disclosure affecting continuing medical educational programs. Program faculty is asked to disclose any affiliations or financial interests they may have in any organization that may have an interest in their comments.
The following information was received from the faculty/planners for the past twelve months:

Planner: Roger Sheldon, MD, owns stock in Intergenetics.
Planner: Margie Miller, MS, CPP, has no significant relationships to disclose.
Presenter: Edmund Messina, MD Course Developer and Narrator, has recieved honoraria from GlaxoSmithKline and Cephalon, Inc.
Presenter: Thomas Roth, PhD, Grants or research support from Merck and Company, served as a consultant for Actelion Pharmaceuticals; Addrenex Pharmaceuticals, Inc.; Bayer Healthcare, BTG, Cephalon, Inc.; Eisai, Inc.; Intracellular Therapies, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Merck and Company, Otsuka America Pharmaceutical, Inc.; Pfizer, Inc.; sanofi-aventis, Sepracor, Inc.; Shire Specialty Pharmaceuticals, Somaxon Pharmaceuticals, Takeda Pharmaceutical Company, TransOral Pharmaceuticals, Inc.; and honoraria from Cephalon, Inc. and sanofi-aventis.
Presenter: Jonathan R L Schwartz, MD, consultant and honoraria from AstraZeneca; Boehringer Ingelheim; Cephalon, Inc.; Jazz Pharmaceuticals; Pfizer, Inc.; GlaxoSmithKline and Teva Pharmaceutical Industries Ltd.
Presenter: Michael J Thorpy, MD, has no significant relationships to disclose.

Commercial Support
This web-based, enduring material activity had originally received support from Cephalon Inc. through an educational grant.

Acknowledgements
This program was filmed and edited by Interactive Video Technology, East Lansing, MI

Course Objectives:
At the completion of this activity, participants will be able to:
1) Use expanded medical history to evaluate patients with suspected Excessive Sleepiness
2) Identify and treat patients with Excessive Sleepiness secondary to Obstructive Sleep Apnea
3) Identify comorbid conditions that cause or exacerbate Excessive Sleepiness

Course Content:
Part 1-How to deal with sleepiness as a complaint;
Part 2-How to uncover sleepiness during routine office visit;
Part 3-How to suspect Obstructive Sleep Apnea (OSA) with co-morbid conditions;
Part 4-How to diagnose OSA and
Part 5-How to manage OSA in primary care.

Estimated time to complete this educational activity is two hours.